SCHEDULE 13G/A 0001140361-25-004890 0001858703 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 03/31/2025 0001094038 Marker Therapeutics, Inc. 57055L206 2450 Holcombe Blvd, Suite BCM-A MS: BCM251 Houston TX 77021 Rule 13d-1(b) Blue Owl Capital Holdings LP DE 1127052 0 1127052 0 1127052 N 9.99 PN The reported securities represent 554,250 shares of common stock ("Common Stock") and 572,802 shares of Common Stock issuable upon exercise of Warrants (as defined below) to purchase shares of Common Stock from the Issuer. The percentage of class is calculated based upon 10,709,005 shares of Common Stock outstanding as of March 18, 2025, as reported on the Issuer's 10-K filed with the Securities and Exchange Commission on March 31, 2025, as increased by the 572,802 shares of Common Stock issuable upon exercise of the Warrants. Marker Therapeutics, Inc. 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas, 77021 Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person." 399 Park Avenue New York, NY 10022 See response to Item 4 on the cover page. N IA See response to Item 9 on the cover page. At a special meeting on March 21, 2025, stockholders approved the issuance of shares of Common Stock upon exercise of warrants held by the Reporting Person, each exercisable to receive one share of Common Stock (the "Warrants"). In this regard, the Reporting Person holds 554,250 shares of Common Stock and 2,570,750 Warrants, which are subject to a conversion limitation that prevents the Reporting Person's beneficial ownership from exceeding 9.99%. As such, the reported securities include only 572,802 shares of Common Stock acquirable upon exercise of Warrants. The filing of this Statement shall not be construed as an admission that the Reporting Person or any of the foregoing are, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Statement. See response to Item 11 on the cover page. See response to Item 5 on the cover page. See response to Item 6 on the cover page. See response to Item 7 on the cover page. See response to Item 8 on the cover page. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Blue Owl Capital Holdings LP /s/ Karen Hager 05/15/2025